59:
In a newly diagnosed non-anticoagulated AF patient, the physician may avoid a ‘trial of warfarin’ (which may expose patients to increased stroke risk during the initial inception phase, with suboptimal anticoagulation control) and make an informed decision between patients likely to do well on a VKA
405:
Ruff, Christian T., et al. "Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the
Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48
51:
This score reflects the need to offer an improved patient care pathway when using oral anticoagulants. While NOACs avoid the need for drug monitoring (e.g. INR monitoring), they have an unstable bioavailability and are not indicated for patients with chronic
353:
Hindricks, Gerhard; Potpara, Tatjana; Dagres, Nikolaos; Arbelo, Elena; Bax, Jeroen J.; Blomström-Lundqvist, Carina; Boriani, Giuseppe; Castella, Manuel; Dan, Gheorghe-Andrei; Dilaveris, Polychronis E.; Fauchier, Laurent (2020-08-29).
271:
Proietti M, Lip G. "Simple decision making between a
Vitamin K Antagonist and Non-Vitamin K Antagonist Oral Anticoagulant (NOACs): Using the SAMe-TT2R2 Score. European Heart Journal - Cardiovascular Pharmac.
433:
Proietti M, Lip G. Simple decision making between a
Vitamin K Antagonist and Non-Vitamin K Antagonist Oral Anticoagulant (NOACs): Using the SAMe-TT2R2 Score. European Heart Journal - Cardiovascular Pharmac.
297:
Proietti M, Lip G. Simple decision making between a
Vitamin K Antagonist and Non-Vitamin K Antagonist Oral Anticoagulant (NOACs): Using the SAMe-TT2R2 Score. European Heart Journal - Cardiovascular Pharmac.
446:
Clarkesmith DE, Pattison HM, Lip GY, Lane DA. "Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One. 2013 Sep 9;8(9):e74037.
237:
Apostolakis, S; Sullivan, RM; Olshansky, B; Lip, GY (Nov 2013). "Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score".
424:
Azoulay L, Dell'Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J. 2014 Jul 21;35(28):1881-7.
284:
Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score"
356:"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)"
415:
2014 AHA/ACC Guideline for the
Management of Patients With Valvular Heart Disease (Journal of the American College of Cardiology). Published on March 3, 2014
36:
e.g. warfarin). It has been suggested that it can aid in the medical decision making between VKAs and new oral anticoagulant/non-VKA oral anticoagulant (
124:
dical history (history of more than two of the following: hypertension, diabetes, CAD, PAD, heart failure, stroke; pulmonary, hepatic, or renal disease)
469:
312:
313:"The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective "Real-World" Inception Cohort Study"
32:
to predict the quality of vitamin K antagonist anticoagulation therapy as measured by time in therapeutic INR range (TTR) (
29:
484:
435:
299:
273:
200:
Improve education regarding anticoagulation control (e.g. a structured educational programme) or select a
189:
69:
33:
41:
166:
Using the above table add together points assigned for different factors to a maximum score of 8.
388:
380:
335:
254:
355:
447:
370:
327:
246:
44:(AF). This score can be used with patients with ≥1 additional stroke risk factors using the
466:
53:
478:
201:
37:
216:
45:
451:
331:
375:
188:
Patients are likely to achieve a high TTR (e.g. >65%) so initiating with a
72:
is perhaps likely to be associated with poor quality anticoagulation control.
384:
392:
339:
258:
250:
48:
score, where oral anticoagulation is recommended or should be considered.
436:
http://ehjcvp.oxfordjournals.org/content/early/2015/03/03/ehjcvp.pvv012
300:
http://ehjcvp.oxfordjournals.org/content/early/2015/03/03/ehjcvp.pvv012
274:
http://ehjcvp.oxfordjournals.org/content/early/2015/03/03/ehjcvp.pvv012
40:
e.g. dabigatran, rivaroxaban, apixaban or edoxaban) in patients with
406:(ENGAGE AF–TIMI 48)." American Heart Journal 160.4 (2010): 635-641
135:reatment (interacting medications e.g. amiodarone)
56:or in patients with valvular replacement surgery.
8:
374:
470:Royal College of Physicians of Edinburgh
173:
87:
229:
7:
14:
204:would be better initial options.
311:Roldán, Vanessa (15 June 2015).
1:
452:10.1371/journal.pone.0074037
332:10.1016/j.amjmed.2015.05.036
91:Condition/influencing factor
467:SAMe-TT2R2 score calculator
146:obacco use (within 2 years)
501:
376:10.1093/eurheartj/ehaa612
30:clinical prediction rule
288:2013 Nov;144(5):1555-63
363:European Heart Journal
192:is likely beneficial.
68:score 0–2) or where a
251:10.1378/chest.13-0054
76:Calculate the SAMe-TT
157:ace (non-Caucasian)
42:atrial fibrillation
180:Action (Untested)
208:
207:
164:
163:
113:ge (<60 years)
492:
454:
444:
438:
431:
425:
422:
416:
413:
407:
403:
397:
396:
378:
360:
350:
344:
343:
317:
308:
302:
295:
289:
282:
276:
269:
263:
262:
234:
174:
88:
500:
499:
495:
494:
493:
491:
490:
489:
475:
474:
463:
458:
457:
445:
441:
432:
428:
423:
419:
414:
410:
404:
400:
358:
352:
351:
347:
326:(11): 1237–43.
315:
310:
309:
305:
296:
292:
283:
279:
270:
266:
236:
235:
231:
226:
213:
172:
86:
83:
79:
67:
63:
25:
21:
12:
11:
5:
498:
496:
488:
487:
485:Anticoagulants
477:
476:
473:
472:
462:
461:External links
459:
456:
455:
439:
426:
417:
408:
398:
369:(5): 373–498.
345:
303:
290:
277:
264:
245:(5): 1555–63.
228:
227:
225:
222:
221:
220:
212:
209:
206:
205:
198:
194:
193:
186:
182:
181:
178:
171:
168:
162:
161:
158:
151:
150:
147:
140:
139:
136:
129:
128:
125:
118:
117:
114:
107:
106:
103:
96:
95:
92:
85:
81:
77:
74:
65:
61:
54:kidney failure
23:
19:
13:
10:
9:
6:
4:
3:
2:
497:
486:
483:
482:
480:
471:
468:
465:
464:
460:
453:
449:
443:
440:
437:
430:
427:
421:
418:
412:
409:
402:
399:
394:
390:
386:
382:
377:
372:
368:
364:
357:
349:
346:
341:
337:
333:
329:
325:
321:
314:
307:
304:
301:
294:
291:
287:
281:
278:
275:
268:
265:
260:
256:
252:
248:
244:
240:
233:
230:
223:
218:
215:
214:
210:
203:
199:
196:
195:
191:
187:
184:
183:
179:
176:
175:
169:
167:
159:
156:
153:
152:
148:
145:
142:
141:
137:
134:
131:
130:
126:
123:
120:
119:
115:
112:
109:
108:
104:
101:
98:
97:
93:
90:
89:
75:
73:
71:
57:
55:
49:
47:
43:
39:
35:
31:
27:
442:
429:
420:
411:
401:
366:
362:
348:
323:
319:
306:
293:
285:
280:
267:
242:
238:
232:
217:CHA2DS2-VASc
177:Score result
165:
154:
143:
132:
121:
110:
99:
58:
50:
46:CHA2DS2-VASc
17:
15:
102:ex (female)
224:References
385:1522-9645
479:Category
393:32860505
340:26087049
320:Am J Med
259:23669885
211:See also
60:(SAMe-TT
170:Results
94:Points
18:SAMe-TT
391:
383:
338:
257:
359:(PDF)
316:(PDF)
286:Chest
239:Chest
219:score
197:>2
84:score
28:is a
26:score
389:PMID
381:ISSN
336:PMID
255:PMID
202:NOAC
38:NOAC
16:The
448:doi
371:doi
328:doi
324:128
247:doi
243:144
190:VKA
185:0-2
70:VKA
34:VKA
481::
387:.
379:.
367:42
365:.
361:.
334:.
322:.
318:.
253:.
241:.
160:2
149:2
138:1
127:1
122:Me
116:1
105:1
450::
395:.
373::
342:.
330::
261:.
249::
155:R
144:T
133:T
111:A
100:S
82:2
80:R
78:2
66:2
64:R
62:2
24:2
22:R
20:2
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.